

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

McCormick et al.

Division of Serial No. 09/522,900

Filed: 8 February 2002

For: Self Antigen Vaccines for Treating B Cell
Lymphomas and Other Cancers

Patent Art Unit: TBA

Examiner: TBA

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.97 and § 1.98, Applicants bring the disclosures listed on completed Forms PTO-1449 to the attention of the Examiner and request that the references be considered and made of record in the instant application. Copies of the references can be found in the parent application.

Since the instant Information Disclosure Statement is being filed prior to issuance of a first Office Action on the merits, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(b) is required.

Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the instant application.


Prompt examination on the merits is requested respectfully.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Dean H. Nakamura".

Dean H. Nakamura
Reg. No. 33,981Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036
(202) 659-9076

Dated: 8 February 2002

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. 42256 SERIAL NO. Div of 09/522,900 APPLICANT McCormick et al. FILING DATE 8 February 2002 GROUP TBA					
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5 8 6 9 2 8 7	9 Feb 1999	Price et al.			JCB21 U.S. PTO 10/067892  02/09/02
		5 2 4 0 8 4 5	31 Aug 1993	Fujii, deceased et al.			
		5 5 4 1 3 0 9	30 Jul 1996	Prasher			
		4 7 6 0 0 2 5	26 Jul 1998	Estell et al.			
		5 5 9 5 8 8 7	21 Jan 1997	Coolidge et al.			
		5 6 5 6 4 5 6	12 Aug 1997	Stout et al.			
		4 7 8 2 1 3 7	1 Nov 1988	Hopp et al.			
		5 6 0 8 0 3 9	4 Mar 1997	Pastan			
		5 9 3 9 4 5 5	17 Aug 1999	Rephaeli			
		5 9 1 2 1 7 2	15 Jun 1999	Eshhar et al.			
		5 9 0 6 9 3 6	25 May 1999	Eshhar et al.			
		5 8 8 5 7 9 3	23 Mar 1999	Griffiths et al.			
		5 7 9 2 6 0 4	11 Aug 1998	Jefferies et al.			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
		Pharmaceutical Biotechnology, "Vaccine Design: The Subunit and Adjuvant Approach." Powell & Newman, Eds. Vol. 6 pp. 389-412, (1995).					
		Proc. Natl. Acad. Sci. USA, McCormick et al., "Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants." Vol. 96, pp. 703-708, (1999).					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 42256		SERIAL NO. Div of 09/522,900	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT McCormick et al.			
		FILING DATE 8 February 2002		GROUP TBA	

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	6	5	8	7	5	3	19 Aug 1997	Faul, et al.			
		5	6	4	8	2	1	9	15 Jul 1997	MacKay et al.			
		5	5	9	9	5	3	8	4 Feb 1997	Faul et al.			
		5	6	3	7	4	5	4	10 Jun 1997	Harley			
		5	5	3	8	8	5	4	23 Jul 1996	Faustman			
		5	2	3	6	8	3	6	17 Aug 1993	Paul			
		5	2	2	9	2	7	2	20 Jul 1993	Paul et al.			
		5	1	3	5	9	1	5	4 Aug 1992	Czarniecki et al.			
		4	3	8	8	4	4	1	14 Jun 1983	Katz			
		4	1	9	1	6	6	8	4 Mar 1980	Katz			
		4	2	2	2	9	0	7	16 Sep 1980	Katz			
		5	6	0	2	0	1	5	11 Feb 1997	Sudhir			
		5	6	9	0	9	3	3	25 Nov 1997	Cobbold et al.			

	DATE CONSIDERED

EXAMINER	
----------	--

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.